PMCB
PharmaCyte Biotech Inc.
Company Overview
| Mkt Cap | $6.66M | Price | $0.65 |
| Volume | 59.53K | Change | +3.17% |
| P/E Ratio | 0.2 | Open | $0.67 |
| Revenue | -- | Prev Close | $0.63 |
| Net Income | $30.7M | 52W Range | $0.63 - $1.90 |
| Div Yield | N/A | Target | -- |
| Overall | 48 | Value | 80 |
| Quality | -- | Technical | 16 |
No chart data available
About PharmaCyte Biotech Inc.
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PMCB | $0.65 | +3.2% | 59.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |